Core Viewpoint - The recent stock placement by 科笛-B (02487) has successfully raised approximately HKD 243 million, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Stock Placement Details - On September 5, shareholders of 科笛-B deposited shares worth HKD 286 million into Huatai Hong Kong, representing 8.26% of the total market value [1] - The placement involved the successful distribution of a total of 28.904 million shares to TruMed Health Innovation Fund LP, Octagon Investments Master Fund LP, and Octagon Private Opportunities Fund II LP at a price of HKD 8.40 per share [1] - The total proceeds from the placement amounted to approximately HKD 243 million, with net proceeds around HKD 240 million after expenses [1]

Core Viewpoint - The company completed a placement of shares, raising approximately HKD 243 million through the sale of 28.904 million shares at a price of HKD 8.40 per share [1] Group 1 - The share placement was successfully completed on September 5, 2025, in accordance with the terms and conditions of the placement agreement [1] - The shares were allocated to TruMed Health Innovation Fund LP, Octagon Investments Master Fund LP, and Octagon Private Opportunities Fund II LP [1] - The total amount raised from the placement was approximately HKD 243 million, with a net amount of about HKD 240 million after expenses [1]

Group 1 - The company completed a placement of shares on September 5, 2025, according to the terms and conditions of the placement agreement [1] - A total of 28.904 million shares were successfully placed to TruMed Health Innovation Fund LP, Octagon Investments Master Fund LP, and Octagon Private Opportunities Fund II LP [1] - The placement price was set at HKD 8.40 per share, resulting in total proceeds of approximately HKD 243 million [1][1]

Group 1 - The company completed a placement of shares on September 5, 2025, according to the terms and conditions of the placement agreement [1] - A total of 28.904 million shares were successfully placed to TruMed Health Innovation Fund LP, Octagon Investments Master Fund LP, and Octagon Private Opportunities Fund II LP at a price of HKD 8.40 per share [1] - The total amount raised from the placement is approximately HKD 243 million, with a net amount of about HKD 240 million after deducting related fees and expenses [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科笛集团 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年9月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) 02487 | 說明 | 普通股 | | | | | A. 已發行股份或庫存股份變動 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | 已發行股份（不包括庫存 ...

本公告或其任何文本概不得直接或間接在美國，或在發放或派發本公告屬違法的任何其他司法 權區內發放或派發。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 本公告並不構成在美國或在有關要約屬違法的任何其他司法權區購買或認購任何證券之提呈要 約或招攬，亦不構成其任何一部分。本公告提及的證券並無且將不會根據不時修訂之《1933年 美國證券法》（「《美國證券法》」）或美國任何其他州之證券法律登記，且不得在美國提呈發售或 出售，惟根據《美國證券法》的規定進行登記，或適用豁免登記，或進行毋須遵守有關登記規定 的交易則除外。本公司無意按照《美國證券法》於美國登記本公告所述任何證券，亦無意於美國 公開發售證券。 Cutia Therapeutics 科笛集團 （於開曼群島註冊成立的有限公司） （股份代號：2487） 完成根據一般授權配售新股 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 整體協調人兼配售代理 茲提述科笛集團（「本公司」）日期為2025 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 科笛集团 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02487 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | | 50,000 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to strategic adjustments and the termination of a partnership with a U.S. skincare brand, while focusing on the commercialization of new products [1][2] Financial Performance - In 1H25, the company achieved revenue of 0.66 million yuan, a year-on-year decrease of 30.6% - The net profit attributable to the parent company was -2.39 million yuan, with adjusted net profit at -2.18 million yuan - The gross margin for 1H25 was 48.4%, down by 4.3 percentage points [1] Strategic Adjustments - The revenue decline was attributed to the company's decision to terminate its agency cooperation with the U.S. skincare brand OMA, reallocating resources to new products CU-40102 and CU-10201, which have received regulatory approval - The company is optimistic about accelerating revenue growth in the second half of the year as these core products move towards commercialization [1][2] Cost Management - The company has optimized its expenses, with sales, management, and R&D costs in 1H25 being 0.92 million, 0.64 million, and 0.79 million yuan respectively, showing year-on-year decreases of 11.4%, 5.0%, and 20.3% - The reduction in sales expenses is attributed to improved investment efficiency in multiple products and strategic marketing preparations for upcoming commercialized products [1] Product Pipeline and Future Outlook - The company has made significant progress in its hair and skin care business, with two key products expected to receive market approval in late 2024 and mid-2025 - The company anticipates that the commercialization of these products will enhance growth potential and contribute positively to financial performance [2] - Projections for net profit from 2025 to 2027 are -2.87 million, -1.00 million, and 1.35 million yuan respectively, maintaining a "buy" rating [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is positioned as a leader in the treatment of skin diseases, with expectations for pipeline commercialization to contribute incremental growth [7] - The company has made strategic adjustments, optimizing expenses while focusing on the commercialization of two core products, which are expected to drive revenue growth in the second half of the year [7] - The company has achieved significant progress in its hair and skin care business, with two major products expected to receive regulatory approval and contribute to growth [7] Financial Performance Summary - Revenue for 2023 is projected at 138 million, with a growth rate of 1110.83%, and is expected to reach 1,070 million by 2027, with a growth rate of 52.40% [6] - The company is expected to report a net profit of -1,964 million in 2023, improving to a profit of 135 million by 2027 [6] - The gross margin for the first half of 2025 was 48.4%, with a decrease of 4.3 percentage points compared to the previous year [7] Product Pipeline and Commercialization - The company anticipates significant contributions from its core pipeline, with two key products expected to be commercialized in the near future [7] - The external 4% minocycline foam and external finasteride spray are set to receive market approval in November 2024 and June 2025, respectively [7] - Additional products in the pipeline include a recombinant collagenase for submental fat accumulation and a new small molecule for atopic dermatitis, with clinical trials progressing [7]

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].